EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

Tsukasa Shibue,Robert A. Weinberg
DOI: https://doi.org/10.1038/nrclinonc.2017.44
IF: 78.8
2017-04-11
Nature Reviews Clinical Oncology
Abstract:Key PointsThe cancer stem cell (CSC) concept posits that a subpopulation of neoplastic cells with stem-cell properties — particularly the capacity to self-renew and give rise to various more differentiated cell types — lies at the apex of a tumour cell hierarchy and serves as a critical driver of tumour progressionThe phenotypic differences between CSCs and the bulk tumour cells that lack 'stemness' (that is, non-CSCs) seem to be attributable predominantly to epigenetic changes caused by the activation of a epithelial-to-mesenchymal transition (EMT) programme in the formerThus, the CSC paradigm provides an explanation for how epigenetic mechanisms can drive the phenotypic diversity of neoplastic cells — an attribute critical for the development of resistance to therapyIndeed, most conventional therapeutics are inefficient in eradicating carcinoma cells that have entered the CSC state via activation of the EMT programme, thereby permitting CSC-dependent disease relapseTargeting the EMT programme in order to eliminate CSCs offers a promising avenue for the improvement of cancer therapy; however, the success of this approach will require an increase in our mechanistic understanding of the EMT–CSC link
oncology
What problem does this paper attempt to address?